Stock MRVL MARVEL BIOSCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Marvel Biosciences Corp.

Equities

MRVL

CA57384M1077

Market Closed - Toronto S.E.
Other stock markets
 19:49:59 01/05/2024 BST 		5-day change 1st Jan Change
0.155 CAD 0.00% Intraday chart for Marvel Biosciences Corp. +14.81% +93.75%
03-26 Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
03-25 Marvel Biosciences Announces Positive Interim Results For MB-204 MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
Marvel Biosciences Announces Positive Interim Results For MB-204
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Positive Interim Results on Tau Phosphorylation with MB-204
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB204
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2023
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204
Marvel Biosciences Completes A Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Marvel Biosciences Completes Short Term Dose Ranging Study For MB-204
Marvel Biosciences Corp. Successfully Completes Its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2022
Marvel Biosciences Corp. Initiates Its Final Fda-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate Mb-204
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate its 7-Day Dose-Ranging, Toxicology Study, Using Rats, for its Lead Molecule MB-204
Marvel Biotechnology Inc. Announces Board Changes
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2022
Marvel Biosciences Corp. Auditor Raises 'Going Concern' Doubt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRVL Stock
  4. News Marvel Biosciences Corp.
  5. Other languages